Researchers identify enzyme that prevents chromosome breaks during DNA copying

Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from ...

Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors

Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits ...
ascopubs.org

DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors. Background: Ceralasertib (AZD6738) is a selective ...
Business Wire

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia ...
Healio

FDA grants fast track designation to ATR-04 for cancer therapy-induced skin rash

Please provide your email address to receive an email when new articles are posted on . ATR-04 has received a fast track designation from the FDA for epidermal growth factor receptor ...
BioWorld

Shanghai Annova Biotechnology patents new ATR kinase inhibitors for cancer

Shanghai Annova Biotechnology Co. Ltd. has disclosed substituted fused heterocyclic compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.
BioWorld

Shanghai Fosun identifies new ATR inhibitors for colon cancer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has patented new tricyclic compounds acting as serine/threonine-protein kinase ATR inhibitors and thus reported to be useful for the treatment of colon ...
Seeking Alpha

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- ...
Business Wire

EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

ROCKLAND, Mass.--(BUSINESS WIRE)--Not intended for UK-based media EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced key clinical ...